Any current/future new fundraising through debt or equity?

Currently, there is no specific mention of any new fundraising plans through debt or equity. Management plans to "go slow" on CAPEX and take a pause to evaluate ongoing investments before committing to new ones. They remain open to new opportunities based on ideas from their creative team or customer interactions. The company has sufficient leverage on the balance sheet, available land, and environmental clearance to undertake future investments if needed. No firm plans are "on the table" or "off the table" as of now, indicating a flexible approach towards future funding depending on opportuni

Future growth expectations in sales/revenue/volumes?

The company anticipates steady growth supported by strong customer trust and a diversified portfolio. Group sales volume grew 4% YoY in Q1 FY26, driven by hydrogenation plant output and initial sales from Mahad facility. They expect the Mahad facility ramp-up to continue positively impacting revenue in coming quarters. EBITDA margin guidance remains at 8%-10%, with expectations to cross this range over time. Incremental sales from recent INR 200+ crore CAPEX are expected to yield 1.7x asset turnover over 2-3 years. Broadly, utilization of non-Mahad plants is optimal at 75%-80%, with Mahad plan

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects incremental sales from recent investments to be about 1.7x over 2 to 3 years. EBITDA margin guidance is maintained at 8% to 10%, with an aim to exceed this over time. Mahad plant is currently ramping up production and expected to achieve positive EBITDA in coming quarters, improving overall profitability. Existing plants are operating at 75%-80% capacity, indicating potential for stable revenues. Focus on launching new products and gaining global acceptance (40+ new products launched in last 5 years running at 70%-80% capacity). Management intends to be cautious with CAPEX,

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Oriental Aromatics Limited. However, the company indicates confidence in its product launches and ongoing engagements, mentioning over 40 products launched in the last 5 years, all globally accepted and running at 70% to 80% plant capacity. They highlight challenges in predicting exact timelines due to factors like RFQ (Request for Quotation) windows and customer engagement cycles. The management is positive about future opportunities but cautious about exact numbers or timelines for orders. The

IN US

Sale is live|00:00:00left today

Oriental Aromatics LtdQ2 FY25Chemicals & Petrochemicals

Oriental Aromatics Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹324P/E: 1440.7Market Cap: ₹1.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company anticipates steady growth supported by strong customer trust and a diversified portfolio.
→Group sales volume grew 4% YoY in Q1 FY26, driven by hydrogenation plant output and initial sales from Mahad facility.
→They expect the Mahad facility ramp-up to continue positively impacting revenue in coming quarters.
→EBITDA margin guidance remains at 8%-10%, with expectations to cross this range over time.
→Incremental sales from recent INR 200+ crore CAPEX are expected to yield 1.7x asset turnover over 2-3 years.
→Broadly, utilization of non-Mahad plants is optimal at 75%-80%, with Mahad plant capacity ramping from 20%-30% towards target.
→The Indian market’s Q2 and Q3 festive/winter season drives higher demand, especially for camphor, fragrances, and aroma chemicals.
→Long-term confidence is high due to over 40 new globally accepted products running at 70%-80% capacity, supporting positive volume and revenue growth.

Margin guidance

Category 3

→The company expects incremental sales from recent investments to be about 1.7x over 2 to 3 years.
→EBITDA margin guidance is maintained at 8% to 10%, with an aim to exceed this over time.
→Mahad plant is currently ramping up production and expected to achieve positive EBITDA in coming quarters, improving overall profitability.
→Existing plants are operating at 75%-80% capacity, indicating potential for stable revenues.
→Focus on launching new products and gaining global acceptance (40+ new products launched in last 5 years running at 70%-80% capacity).
→Management intends to be cautious with CAPEX, focusing on optimizing current investments before new expansions.
→Revenue growth of about 1.7x is linked to asset turnover expectations from new capacities.
→Profitability and margin improvements expected as new plants stabilize and market acceptance grows.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, there is no specific mention of any new fundraising plans through debt or equity.
→Management plans to "go slow" on CAPEX and take a pause to evaluate ongoing investments before committing to new ones.
→They remain open to new opportunities based on ideas from their creative team or customer interactions.
→The company has sufficient leverage on the balance sheet, available land, and environmental clearance to undertake future investments if needed.
→No firm plans are "on the table" or "off the table" as of now, indicating a flexible approach towards future funding depending on opportunities.
→Past CAPEX cycles have seen postponements and optimizations, particularly at the Mahad multipurpose plant, suggesting prudent capital management.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Oriental Aromatics Limited.
→However, the company indicates confidence in its product launches and ongoing engagements, mentioning over 40 products launched in the last 5 years, all globally accepted and running at 70% to 80% plant capacity.
→They highlight challenges in predicting exact timelines due to factors like RFQ (Request for Quotation) windows and customer engagement cycles.
→The management is positive about future opportunities but cautious about exact numbers or timelines for orders.
→The company also emphasizes ongoing customer trust and engagement, especially in fragrance and aroma chemicals, suggesting a steady inflow of business but no specific order backlog figures disclosed.
→They are watching market conditions and supply chain dynamics closely to evaluate CAPEX and related order fulfillment capabilities.

Capex plans

- The company plans to **go slow on CAPEX in the current year**, opting to **pause and evaluate ongoing investments** before moving forward. - There is **no firm CAPEX plan currently on the table**, but management remains **open to opportunities** identified by their creative team or through global customer interactions. - The **balance sheet and P&L have leverage**, and the company owns **land and environmental clearances (EC)** to support future investments. - Past CAPEX includes a **brownfield project at Baroda** (hydrogenation facility) and a **greenfield expansion at Mahad** (single product plant Phase 1). - Some previously planned CAPEX projects, such as a **multi-purpose plant at Mahad, have been postponed or optimized**, leading to better cost control. - Management is **open but currently not inclined towards CDMO/CMO tie-ups**; prefer to make in-house to ensure sustainability. In summary, current approach is cautious with a pause but strategic openness to new investments.

How does Oriental Aromatics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Oriental Aromatics Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Oriental Aromatics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio